Stuart M. Henderson
Contatto Relazioni con gli Investitori presso PASSAGE BIO, INC.
Provenienza dei contatti di primo grado di Stuart M. Henderson
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 31 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Stuart M. Henderson tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Scout Bio, Inc.
 Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Chairman Director/Board Member Founder | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| University of Pennsylvania | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Private Equity Analyst Private Equity Investor | |
| SPRINGWORKS THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer | |
SpringWorks Therapeutics LLC
 SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Biotechnology | Director/Board Member Chief Executive Officer | |
Nutrinia Ltd.
 Nutrinia Ltd. Pharmaceuticals: MajorHealth Technology Nutrinia Ltd. develops bioactive feed supplements for infant formulas and animal feed. The firm is involved in broad intellectual property protection, industrial processes envelopment, conducting additional clinical trials and obtaining regulatory approval for the supplementation of pre-term and infant formulas with Insulin. The company was founded by Naim Shehadeh in 2003 and is headquartered in Ramat-Gan, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| University of California, Los Angeles | College/University | Undergraduate Degree Undergraduate Degree | |
| CHEMOMAB THERAPEUTICS LTD. | Biotechnology | Chairman Director/Board Member | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
| VAXCYTE, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SHIRE | Pharmaceuticals: Major | Public Communications Contact General Counsel | |
| University of Michigan | College/University | Masters Business Admin Doctorate Degree | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin | |
| Stanford University | College/University | Undergraduate Degree Doctorate Degree | |
| Rutgers State University of New Jersey | College/University | Masters Business Admin Masters Business Admin | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree | |
| The Rockefeller University | College/University | Doctorate Degree Doctorate Degree | |
| MODERNA, INC. | Biotechnology | Corporate Officer/Principal | |
| AMBIT BIOSCIENCES CORP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Halda Therapeutics LLC
 Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | Medical/Nursing Services | Director/Board Member | |
| McGill University | College/University | Undergraduate Degree | |
| DISC MEDICINE, INC. | Biotechnology | Director/Board Member | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| ARS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Credit Suisse Asset Management LLC
 Credit Suisse Asset Management LLC Investment ManagersFinance Founded in 1999, Credit Suisse Asset Management LLC (CSAM) is a registered investment advisor headquartered in New York City. The firm is an indirect wholly-owned subsidiary of Credit Suisse Group AG (NYSE: CS), a publicly owned foreign bank holding company based in Switzerland. | Investment Managers | Corporate Officer/Principal | |
| RALLYBIO CORPORATION | Biotechnology | Director/Board Member | |
| Halda Therapeutics OpCo, Inc. | Director/Board Member | ||
| CTI BIOPHARMA CORP. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Access Industries LLC | Corporate Officer/Principal | ||
| MORGAN STANLEY | Investment Managers | Corporate Officer/Principal | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Columbia Law School | College/University | Graduate Degree | |
| Tufts University School of Medicine | College/University | Doctorate Degree | |
| Colgate University | College/University | Undergraduate Degree | |
Deerfield Management Co. LP
 Deerfield Management Co. LP Investment ManagersFinance Deerfield Management Co. LP (Deerfield) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Peter Drake in 1994. They are wholly owned by James E. Flynn and are controlled by its general partner, Flynn Management LLC. Deerfield provides discretionary investment management services in the healthcare sector to domestic and offshore private pooled investment vehicles and their related alternative investment vehicles. | Investment Managers | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Stati Uniti | 42 |
| Svizzera | 4 |
| Israele | 3 |
| Irlanda | 2 |
| Francia | 2 |
Settori
| Health Technology | 29 |
| Consumer Services | 14 |
| Finance | 6 |
| Commercial Services | 2 |
| Health Services | 2 |
Posizioni
| Director/Board Member | 191 |
| Independent Dir/Board Member | 68 |
| Corporate Officer/Principal | 68 |
| Chief Tech/Sci/R&D Officer | 39 |
| Chairman | 25 |
Contatti più connessi
| Insiders | |
|---|---|
| Patrick Heron | 42 |
| Stephen P. Squinto | 40 |
| Thomas Woiwode | 39 |
| Tadataka Yamada | 36 |
| Liam Ratcliffe | 32 |
| Maxine Gowen | 23 |
| Eliseo Salinas | 22 |
| Sandipkumar S. Kapadia | 19 |
| Athena Countouriotis | 17 |
| Michael Kamarck | 15 |
| Saqib Islam | 15 |
| Derrell Porter | 14 |
| Jill Quigley | 11 |
| Bruce Goldsmith | 10 |
| Gary Romano | 7 |
- Borsa valori
- Insiders
- Stuart M. Henderson
- Connessioni Società